NextCure Q3 2023 Earnings Report

NextCure EPS Results

• Actual EPS: -$0.51
• Consensus EPS: -$0.64
• Beat/Miss: Beat by +$0.13
• One Year Ago EPS: N/A

NextCure Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

NextCure Announcement Details

• Quarter: Q3 2023
• Date: 11/2/2023
• Time: N/A
• Conference Call Date: Thursday, November 2, 2023
• Conference Call Time: 5:00PM ET

NextCure (NASDAQ:NXTC) (NASDAQ: NXTC) is a clinical‐stage biotechnology company dedicated to discovering and developing immuno‐oncology therapies that harness the body’s immune system to fight cancer. Utilizing its proprietary immune modulation discovery platforms, NextCure identifies novel targets and advances both antibody and small‐molecule candidates designed to either stimulate antitumor immunity or counteract tumor‐induced immune suppression. The company’s scientific approach rests on deep insights into the molecular pathways that regulate immune cell function within the tumor microenvironment.

The company’s pipeline comprises multiple clinical and preclinical programs. Lead clinical candidate NX‐1607 is an antibody targeting a novel immune checkpoint receptor, currently undergoing dose‐escalation studies in patients with advanced solid tumors. NextCure has also initiated early‐stage trials for NX‐2127, a targeted protein degrader aimed at key immune regulatory proteins, and NX‐5948, a small molecule designed to modulate innate immune pathways. Parallel preclinical efforts explore next-generation therapies for both oncology and select inflammatory diseases.

Founded in 2011 and headquartered in Beltsville, Maryland, NextCure has built a multidisciplinary leadership team with extensive experience in drug discovery, clinical development and regulatory affairs. The company’s executives and advisory board members bring backgrounds from leading pharmaceutical and biotech organizations, supporting its translational research and clinical trial activities. NextCure operates research facilities in the U.S. and maintains strategic collaborations with global pharmaceutical partners to accelerate the development of its immuno‐oncology candidates.

NextCure’s mission is to transform cancer treatment by advancing therapies that precisely engage the immune system against tumors, while minimizing off‐target effects. With a robust platform, an expanding pipeline and collaborative alliances, the company aims to deliver new treatment options for patients with hard‐to‐treat malignancies and to broaden the impact of immuno‐oncology across multiple tumor types.